Abstract
AbstractExtended infusion of piperacillin/tazobactam over 4 h has been proposed as an alternate mode of administration to the 30-min intermittent infusion to optimize treatment effects in patients with gram-negative bacterial infections. The study aimed to evaluate the extended infusion regimen of piperacillin/tazobactam in standings of efficacy, safety, and cost to the intermittent one in the treatment of gram-negative bacterial infections. A prospective randomized comparative study was performed on 53 patients, 27 in the intermittent infusion group and 26 in the extended infusion group. The primary outcome was the mean number of days to clinical success and the percentage of patients who were clinically cured after treatment. The secondary outcomes included mortality, readmission within 30-days, and cost-effectiveness analysis based on the mean number of days to clinical success. The clinical success rate was comparable in the two groups. Days on extended infusion were significantly lower than intermittent infusion (5.7 vs 8.9 days, respectively, p = 0.0001) as well as days to clinical success (4.6 vs 8.5 days, respectively, p = 0.026). The extended infusion was superior to the intermittent infusion regarding cost-effectiveness ratio ($1835.41 and $1914.09/expected success, respectively). The more cost-effective regimen was the extended infusion. Both regimens had comparable clinical and microbiological outcomes.
Funder
British University in Egypt
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Macvane, S. H. Antimicrobial resistance in the intensive care unit. J. Intensive Care Med. 32, 25–37 (2017).
2. Anton, Y. P. & David, C. H. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med. Rev. 2, 2 (2010).
3. Deelen, J. W. T. et al. The burden of bacteremic and non-bacteremic gram-negative infections: A prospective multicenter cohort study in a low-resistance country. J. Infect. 81, 895–901 (2020).
4. Yang, H., Zhang, C., Zhou, Q., Wang, Y. & Chen, L. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: A systematic review and meta-analysis. PLoS ONE 10, 1–14 (2015).
5. Bao, H., Lv, Y., Wang, D., Xue, J. & Yan, Z. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: A randomized controlled trial. Eur. J. Clin. Microbiol. Infect. Dis. 36, 459–466 (2017).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献